Overview

A Rollover Study to Provide Chronic T-1249 to Patients Who Completed Study T1249-102

Status:
Unknown status
Trial end date:
1969-12-31
Target enrollment:
0
Participant gender:
All
Summary
Patients who complete study T1249-102 (must be currently failing a T-20 containing regimen to participate in this study) will receive T-1249 at a dose of 200mg daily in combination with a background antiretroviral regimen for 96 weeks. Only patients that participated in study T1249-102 can participate in study T1249-105.
Phase:
Phase 1/Phase 2
Accepts Healthy Volunteers?
No
Details
Lead Sponsor:
Trimeris
Criteria
Inclusion Criteria:

- Completion T1249-102;

- Currently failing a T-20 containing regimen

Exclusion Criteria:

- Non-completion of T1249-102.